ranibizumab

FDA Drug Profile

Drug Details

Generic Name
ranibizumab
Brand Names
N/A
Application Number
Sponsor
POLPHARMA BIOLOGICS SA
NDC Codes
2
Dosage Forms
SOLUTION, CONCENTRATE, INJECTION, SOLUTION
Routes
N/A
Active Ingredients
RANIBIZUMAB

Indications and Usage

1 INDICATIONS AND USAGE BYOOVIZ is indicated for the treatment of patients with: BYOOVIZ, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Myopic Choroidal Neovascularization (mCNV) ( 1.3 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Myopic Choroidal Neovascularization (mCNV)